
Innoviva (INVA) just posted third quarter results that shifted from a profit to a sizeable loss, even as it completed a multi year share repurchase program affecting more than 5% of its equity base.
Investors just watched Innoviva’s share price fall about 9% over the past month and about 10% over the past quarter, a slide that lines up with the swing from profit to loss in the latest results, even as the multi quarter buyback program wrapped up.
Compare Innoviva’s sharp swing into a quarterly loss with other hand picked healthcare stocks by scanning 36 healthcare AI stocks, which are also wrestling with earnings volatility and sentiment shifts right now.
For Innoviva, a double hit of weaker earnings and a completed buyback has arrived just as the share price has drifted lower. Is that slide mainly about the business, or has sentiment swung too far?
Innoviva’s last close of $19.03 sits well below the fair value of $35 in the analyst consensus Narrative on Simply Wall St. That estimate is built using a 7.2% discount rate and detailed revenue and earnings forecasts.
Analysts expect Innoviva to use its respiratory royalty stream, its growing Innoviva Specialty Therapeutics business, and its healthcare investment portfolio to support a multi-pillar model that can fund further expansion over time.
The main requirement is effective execution on scaling Innoviva Specialty Therapeutics and converting its healthcare investments, including Armata and Nortiva Bio, into durable cash flow streams while maintaining disciplined capital allocation.
See why 3 investors see Innoviva as 46% undervalued.
Result: Fair Value of $35 (UNDERVALUED)
Still, the narrative around Innoviva depends heavily on collecting about US$1b in respiratory royalties, as well as on Armata and Nortiva Bio progressing from early stage projects into durable cash flows.
Find out about the key risks to this Innoviva narrative.
Mixed signals on Innoviva can either be a warning or an opening. Move quickly, review the full picture, and weigh both the 4 key rewards and 1 important warning sign.
Do not stop with Innoviva. Use the Simply Wall St screener to quickly spot other opportunities that match the type of portfolio you actually want to build.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com